Morphosys AG (GB:0NDV) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
In the event that MorphoSys AG’s ordinary shares remain post-Novartis takeover offer, a significant decrease in liquidity and market value is anticipated. The reduced free float could lead to difficulties for minority shareholders in selling their shares and potentially result in their exclusion from German SDAX & TecDAX stock indices, causing further adverse effects on share price due to potential index fund sell-offs. Similarly, the American Depositary Shares (ADSs) listed on Nasdaq may suffer from reduced liquidity, increased volatility, and the risk of trading suspension or delisting, compounding the risk for investors holding these securities.
Overall, Wall Street has a Hold consensus rating on GB:0NDV stock based on 1 Buy and 6 Holds.
To learn more about Morphosys AG’s risk factors, click here.